Aquinox Pharmaceuticals, Inc. (AQXP) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research cut shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) from a hold rating to a sell rating in a report issued on Tuesday.

According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “

A number of other research firms have also recently weighed in on AQXP. ValuEngine cut Aquinox Pharmaceuticals from a hold rating to a sell rating in a report on Friday, September 15th. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, August 8th. Finally, BidaskClub cut Aquinox Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, July 28th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Aquinox Pharmaceuticals presently has an average rating of Hold and a consensus target price of $22.25.

Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 14.05 on Tuesday. Aquinox Pharmaceuticals has a 12 month low of $9.83 and a 12 month high of $19.97. The firm’s 50-day moving average price is $14.24 and its 200-day moving average price is $14.41. The firm’s market cap is $329.67 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.59) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.59). Equities research analysts predict that Aquinox Pharmaceuticals will post ($2.15) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://ledgergazette.com/2017/10/11/aquinox-pharmaceuticals-inc-aqxp-downgraded-by-zacks-investment-research-to-sell.html.

Several large investors have recently bought and sold shares of AQXP. Nexthera Capital LP bought a new position in shares of Aquinox Pharmaceuticals in the 2nd quarter worth $1,276,000. Sphera Funds Management LTD. bought a new position in shares of Aquinox Pharmaceuticals in the 2nd quarter worth $874,000. Vanguard Group Inc. boosted its position in shares of Aquinox Pharmaceuticals by 6.6% in the 2nd quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after purchasing an additional 17,455 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Aquinox Pharmaceuticals by 10.0% in the 1st quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock worth $2,028,000 after purchasing an additional 11,035 shares during the last quarter. Finally, Investment Centers of America Inc. bought a new position in shares of Aquinox Pharmaceuticals in the 1st quarter worth $172,000. Institutional investors and hedge funds own 95.15% of the company’s stock.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-

According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “

A number of other research firms have also recently weighed in on AQXP. ValuEngine cut Aquinox Pharmaceuticals from a hold rating to a sell rating in a report on Friday, September 15th. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, August 8th. Finally, BidaskClub cut Aquinox Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, July 28th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Aquinox Pharmaceuticals presently has an average rating of Hold and a consensus target price of $22.25.

Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 14.05 on Tuesday. Aquinox Pharmaceuticals has a 12 month low of $9.83 and a 12 month high of $19.97. The firm’s 50-day moving average price is $14.24 and its 200-day moving average price is $14.41. The firm’s market cap is $329.67 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.59) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.59). Equities research analysts predict that Aquinox Pharmaceuticals will post ($2.15) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://ledgergazette.com/2017/10/11/aquinox-pharmaceuticals-inc-aqxp-downgraded-by-zacks-investment-research-to-sell.html.

Several large investors have recently bought and sold shares of AQXP. Nexthera Capital LP bought a new position in shares of Aquinox Pharmaceuticals in the 2nd quarter worth $1,276,000. Sphera Funds Management LTD. bought a new position in shares of Aquinox Pharmaceuticals in the 2nd quarter worth $874,000. Vanguard Group Inc. boosted its position in shares of Aquinox Pharmaceuticals by 6.6% in the 2nd quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after purchasing an additional 17,455 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Aquinox Pharmaceuticals by 10.0% in the 1st quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock worth $2,028,000 after purchasing an additional 11,035 shares during the last quarter. Finally, Investment Centers of America Inc. bought a new position in shares of Aquinox Pharmaceuticals in the 1st quarter worth $172,000. Institutional investors and hedge funds own 95.15% of the company’s stock.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply